FILTER
FILTERED INTERVIEW RESULTS
Stephen Smithyman
CEO, KANU EQUIPMENT
Kanu Equipment comments on the challenges and opportunities in Africa for a mining and construction dealership.
Luke Alexander
PRESIDENT, CEO AND DIRECTOR, NEWCORE GOLD LTD.
Newcore Gold enthuses about the prospects of its major drilling campaign at its Enchi gold project in Ghana.
Simon Meadows Smith
MANAGING DIRECTOR, SEMS EXPLORATION SERVICES
SEMS Exploration is a consultancy and exploration services company in West Africa. Geologist and Managing Director, Simon Meadows Smith, walks us through the trends he observes in the region.
George Kwatia
PARTNER, PWC GHANA
PwC Ghana comments on how the mining industry and the Ghanian government are managing the impacts of the pandemic.
John Kwofie & Ivan Doku
PRINCIPAL MINING ENGINEER AND COUNTRY MANAGER & PRINCIPAL RESOURCE GEOLOGIST AND COUNTRY MANAGER-DESIGNATE, SRK CONSULTING
An overview of the firm’s activities in West Africa.
Stéphane Cervellera
WESTERN AFRICA MANAGER, TITANOBEL
Titanobel explains its plans to expand its explosive business around the world.
Vincent Mascolo
CEO, IRON RIDGE RESOURCES
IronRidge’s focus on lithium and gold gives investors exposure to rapidly growing lithium technology markets while hedging prominent global economic uncertainty via a large gold exploration portfolio.
James Wallbank
MANAGING PARTNER, IBAERA CAPITAL
Ibaera Capital explains its investment strategy as it opens a new and larger fund.
Ama Nketiah
REGIONAL MANAGER, KNIGHT PIÉSOLD (KP) GHANA
Knight Piésold Ghana provides geotechnical and environmental consultancy services to the mining, power, water resources, infrastructure, and oil and gas industries in West Africa.
Alfred Baku
EXECUTIVE VICE PRESIDENT AND HEAD OF WEST AFRICA, GOLD FIELDS
Gold Fields outlines progress at its projects in Ghana.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
